JP2016523907A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016523907A5 JP2016523907A5 JP2016523869A JP2016523869A JP2016523907A5 JP 2016523907 A5 JP2016523907 A5 JP 2016523907A5 JP 2016523869 A JP2016523869 A JP 2016523869A JP 2016523869 A JP2016523869 A JP 2016523869A JP 2016523907 A5 JP2016523907 A5 JP 2016523907A5
- Authority
- JP
- Japan
- Prior art keywords
- dioxo
- carbazole
- carboxamide
- fluoro
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- -1 2-hydroxypropan-2-yl Chemical group 0.000 claims 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- ZRYMMWAJAFUANM-INIZCTEOSA-N (7s)-3-fluoro-4-[3-(8-fluoro-1-methyl-2,4-dioxoquinazolin-3-yl)-2-methylphenyl]-7-(2-hydroxypropan-2-yl)-6,7,8,9-tetrahydro-5h-carbazole-1-carboxamide Chemical compound C1[C@@H](C(C)(C)O)CCC2=C1NC1=C2C(C2=C(C(=CC=C2)N2C(C3=CC=CC(F)=C3N(C)C2=O)=O)C)=C(F)C=C1C(N)=O ZRYMMWAJAFUANM-INIZCTEOSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- WQLRVJLVBJTPDC-INIZCTEOSA-N CC(C)([C@@H](CC1)Cc2c1c1c(-c3cccc(N(C(C=C4N5C=CC=C4Cl)=O)C5=O)c3C)c(F)cc(C(N)=O)c1[nH]2)O Chemical compound CC(C)([C@@H](CC1)Cc2c1c1c(-c3cccc(N(C(C=C4N5C=CC=C4Cl)=O)C5=O)c3C)c(F)cc(C(N)=O)c1[nH]2)O WQLRVJLVBJTPDC-INIZCTEOSA-N 0.000 description 2
- UGOUGTGKDWPLNV-UCFFOFKASA-N CC(C)([C@@H](CC1)Cc2c1c(C(c1cccc(N(C(C=C3N4C=CC=C3F)=O)C4=O)c1C)=C(CC1C(N)=O)F)c1[nH]2)O Chemical compound CC(C)([C@@H](CC1)Cc2c1c(C(c1cccc(N(C(C=C3N4C=CC=C3F)=O)C4=O)c1C)=C(CC1C(N)=O)F)c1[nH]2)O UGOUGTGKDWPLNV-UCFFOFKASA-N 0.000 description 1
- OILCFDXBRQHLMC-INIZCTEOSA-N CC(C)([C@@H](CC1)Cc2c1c1c(-c3cccc(N(C(C=C4N5C=CC=C4F)=O)C5=O)c3C)c(F)cc(C(N)=O)c1[nH]2)O Chemical compound CC(C)([C@@H](CC1)Cc2c1c1c(-c3cccc(N(C(C=C4N5C=CC=C4F)=O)C5=O)c3C)c(F)cc(C(N)=O)c1[nH]2)O OILCFDXBRQHLMC-INIZCTEOSA-N 0.000 description 1
- FPEKPVWYNZREQW-OAHLLOKOSA-N CC(C)([C@H](CC1)Cc2c1c1c(-c3cccc(N(C(c4cccc(F)c4N4)=O)C4=O)c3C)c(F)cc(C(N)=O)c1[nH]2)O Chemical compound CC(C)([C@H](CC1)Cc2c1c1c(-c3cccc(N(C(c4cccc(F)c4N4)=O)C4=O)c3C)c(F)cc(C(N)=O)c1[nH]2)O FPEKPVWYNZREQW-OAHLLOKOSA-N 0.000 description 1
- CJKYBOFIPNUNMH-NRFANRHFSA-N CC(C)(c(cc1)cc2c1c(C(c1cccc(N(C(C=C3N4C=CC=C3Cl)=O)C4=O)c1C)=C(C)C[C@@H]1C(N)=O)c1[nH]2)O Chemical compound CC(C)(c(cc1)cc2c1c(C(c1cccc(N(C(C=C3N4C=CC=C3Cl)=O)C4=O)c1C)=C(C)C[C@@H]1C(N)=O)c1[nH]2)O CJKYBOFIPNUNMH-NRFANRHFSA-N 0.000 description 1
- RPQWRQVJFPCCAW-NRFANRHFSA-N CC(C)(c1ccc2c(C(c3cccc(N(C(c4cccc(F)c4N4)=O)C4=O)c3C)=C(C)C[C@@H]3C(N)=O)c3[nH]c2c1)O Chemical compound CC(C)(c1ccc2c(C(c3cccc(N(C(c4cccc(F)c4N4)=O)C4=O)c3C)=C(C)C[C@@H]3C(N)=O)c3[nH]c2c1)O RPQWRQVJFPCCAW-NRFANRHFSA-N 0.000 description 1
- CJSGAKAHWDXMND-IBGZPJMESA-N Cc(c(C(c1c([C@H](C2)C(N)=O)[nH]c3cc(CCO)ccc13)=C2F)ccc1)c1N(C(C=C1N2C=CC=C1F)=O)C2=O Chemical compound Cc(c(C(c1c([C@H](C2)C(N)=O)[nH]c3cc(CCO)ccc13)=C2F)ccc1)c1N(C(C=C1N2C=CC=C1F)=O)C2=O CJSGAKAHWDXMND-IBGZPJMESA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361839141P | 2013-06-25 | 2013-06-25 | |
| US61/839,141 | 2013-06-25 | ||
| PCT/US2014/043978 WO2014210085A1 (en) | 2013-06-25 | 2014-06-25 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds useful as kinase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016523907A JP2016523907A (ja) | 2016-08-12 |
| JP2016523907A5 true JP2016523907A5 (en:Method) | 2017-07-06 |
| JP6353529B2 JP6353529B2 (ja) | 2018-07-04 |
Family
ID=51210830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016523869A Expired - Fee Related JP6353529B2 (ja) | 2013-06-25 | 2014-06-25 | 置換されたテトラヒドロカルバゾールおよびカルバゾールカルボキサミド化合物 |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US9334290B2 (en:Method) |
| EP (1) | EP3013814B1 (en:Method) |
| JP (1) | JP6353529B2 (en:Method) |
| KR (1) | KR102346508B1 (en:Method) |
| CN (1) | CN105358546B (en:Method) |
| AR (1) | AR096721A1 (en:Method) |
| AU (1) | AU2014302548B2 (en:Method) |
| BR (1) | BR112015030723A8 (en:Method) |
| CA (1) | CA2916500A1 (en:Method) |
| CL (1) | CL2015003635A1 (en:Method) |
| CY (1) | CY1119371T1 (en:Method) |
| DK (1) | DK3013814T3 (en:Method) |
| EA (1) | EA026729B1 (en:Method) |
| ES (1) | ES2636652T3 (en:Method) |
| HR (1) | HRP20171031T1 (en:Method) |
| HU (1) | HUE034460T2 (en:Method) |
| IL (1) | IL243296B (en:Method) |
| LT (1) | LT3013814T (en:Method) |
| MA (1) | MA38648B1 (en:Method) |
| MY (1) | MY176631A (en:Method) |
| PE (1) | PE20160519A1 (en:Method) |
| PH (1) | PH12015502630A1 (en:Method) |
| PL (1) | PL3013814T3 (en:Method) |
| PT (1) | PT3013814T (en:Method) |
| RS (1) | RS56371B1 (en:Method) |
| SI (1) | SI3013814T1 (en:Method) |
| SM (1) | SMT201700422T1 (en:Method) |
| TN (1) | TN2015000529A1 (en:Method) |
| TW (1) | TWI648272B (en:Method) |
| UY (1) | UY35625A (en:Method) |
| WO (1) | WO2014210085A1 (en:Method) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014210087A1 (en) | 2013-06-25 | 2014-12-31 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
| LT3209651T (lt) * | 2014-10-24 | 2020-01-10 | Bristol-Myers Squibb Company | Karbazolo dariniai |
| JP6592512B2 (ja) | 2014-10-24 | 2019-10-16 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 三環式アトロプ異性体の化合物 |
| LT3461821T (lt) | 2014-10-24 | 2020-08-10 | Bristol-Myers Squibb Company | Indolo karboksamido junginiai, naudotini kaip kinazės inhibitoriai |
| US10842963B2 (en) | 2016-07-01 | 2020-11-24 | Brio Device, LLC | Intubation stylet with video feed |
| CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
| US11590167B2 (en) | 2016-12-03 | 2023-02-28 | Juno Therapeutic, Inc. | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors |
| US10875843B2 (en) | 2016-12-20 | 2020-12-29 | Bristol-Myers Squibb Company | Process for preparing tetrahydrocarbazole carboxamide compound |
| EP3789040A4 (en) | 2018-04-27 | 2022-03-09 | ONO Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT |
| CA3224985C (en) | 2018-07-31 | 2025-11-18 | Loxo Oncology, Inc. | SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE |
| WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| US20240216330A1 (en) | 2021-04-02 | 2024-07-04 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
| AU2023220628A1 (en) * | 2022-02-15 | 2024-05-23 | F. Hoffmann-La Roche Ag | Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| CA2140722A1 (en) | 1994-01-24 | 1995-07-25 | Joseph A. Jakubowski | Beta-carboline thromboxane synthase inhibitors |
| US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| US7393848B2 (en) | 2003-06-30 | 2008-07-01 | Cgi Pharmaceuticals, Inc. | Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds |
| WO2005047290A2 (en) | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
| US7713973B2 (en) | 2004-10-15 | 2010-05-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| CA2587192A1 (en) | 2004-11-10 | 2006-05-18 | Cgi Pharmaceuticals, Inc. | Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity |
| AP2334A (en) | 2004-12-17 | 2011-12-06 | Glenmark Pharmaceuticals Sa | Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders. |
| US7947835B2 (en) | 2005-03-10 | 2011-05-24 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| JP2009508872A (ja) | 2005-09-16 | 2009-03-05 | セレネックス， インコーポレイテッド | カルバゾール誘導体 |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US8518964B2 (en) | 2005-11-22 | 2013-08-27 | Merck Sharp & Dohme Corp. | Tricyclic compounds useful as inhibitors of kinases |
| CA2663178C (en) | 2006-09-11 | 2016-01-12 | Matrix Laboratories Ltd. | Dibenzofuran derivatives as inhibitors of pde-4 and pde-10 |
| WO2008033858A2 (en) | 2006-09-11 | 2008-03-20 | Cgi Pharmaceuticals, Inc. | Kinase inhibitors, and methods of using and identifying kinase inhibitors |
| US20090062251A1 (en) | 2007-08-17 | 2009-03-05 | Astrazeneca Ab | Novel Compounds 002 |
| EP2231143B1 (en) | 2007-12-13 | 2013-07-03 | Merck Sharp & Dohme Corp. | 5H-pyrido[4,3-b]indoles as INHIBITORS OF JANUS KINASES |
| FI2247558T4 (fi) | 2008-02-14 | 2024-09-19 | Lilly Co Eli | Uusia kuvantamisaineita neurologisen toimintahäiriön toteamiseen |
| GB0809360D0 (en) | 2008-05-22 | 2008-07-02 | Isis Innovation | Calcium modulation |
| EP2151441A1 (en) | 2008-08-06 | 2010-02-10 | Julius-Maximilians-Universität Würzburg | Beta-carbolin-derivates as substrates for an enzyme |
| EP2391602B1 (en) * | 2008-12-19 | 2013-12-04 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
| CN101475571B (zh) | 2009-01-21 | 2011-06-22 | 中国药科大学 | β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途 |
| US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
| US9029387B2 (en) | 2010-03-26 | 2015-05-12 | Merck Patent Gmbh | Benzonaphthyridinamines as autotaxin inhibitors |
| WO2011159857A1 (en) * | 2010-06-16 | 2011-12-22 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
| EP2455378A1 (en) | 2010-11-03 | 2012-05-23 | Philip Morris Products S.A. | Carbazole and carboline derivatives, and preparation and therapeutic applications thereof |
| CA2817896A1 (en) | 2010-11-15 | 2012-05-24 | Viiv Healthcare Uk Limited | Inhibitors of hiv replication |
| ES2590491T3 (es) | 2011-05-17 | 2016-11-22 | F. Hoffmann-La Roche Ag | Inhibidores de la tirosina quinasa de Bruton |
| WO2013054185A1 (en) | 2011-10-13 | 2013-04-18 | Pfizer, Inc. | Pyrimidine and pyridine derivatives useful in therapy |
-
2014
- 2014-06-24 UY UY0001035625A patent/UY35625A/es unknown
- 2014-06-24 TW TW103121681A patent/TWI648272B/zh not_active IP Right Cessation
- 2014-06-24 AR ARP140102388A patent/AR096721A1/es unknown
- 2014-06-25 CN CN201480035611.8A patent/CN105358546B/zh not_active Expired - Fee Related
- 2014-06-25 LT LTEP14740094.9T patent/LT3013814T/lt unknown
- 2014-06-25 KR KR1020167001632A patent/KR102346508B1/ko not_active Expired - Fee Related
- 2014-06-25 RS RS20170904A patent/RS56371B1/sr unknown
- 2014-06-25 CA CA2916500A patent/CA2916500A1/en not_active Abandoned
- 2014-06-25 TN TN2015000529A patent/TN2015000529A1/en unknown
- 2014-06-25 JP JP2016523869A patent/JP6353529B2/ja not_active Expired - Fee Related
- 2014-06-25 US US14/314,602 patent/US9334290B2/en active Active
- 2014-06-25 EP EP14740094.9A patent/EP3013814B1/en active Active
- 2014-06-25 EA EA201592287A patent/EA026729B1/ru not_active IP Right Cessation
- 2014-06-25 MY MYPI2015704738A patent/MY176631A/en unknown
- 2014-06-25 HU HUE14740094A patent/HUE034460T2/en unknown
- 2014-06-25 WO PCT/US2014/043978 patent/WO2014210085A1/en not_active Ceased
- 2014-06-25 DK DK14740094.9T patent/DK3013814T3/en active
- 2014-06-25 PE PE2015002665A patent/PE20160519A1/es active IP Right Grant
- 2014-06-25 PL PL14740094T patent/PL3013814T3/pl unknown
- 2014-06-25 AU AU2014302548A patent/AU2014302548B2/en not_active Ceased
- 2014-06-25 PT PT147400949T patent/PT3013814T/pt unknown
- 2014-06-25 SI SI201430268T patent/SI3013814T1/sl unknown
- 2014-06-25 MA MA38648A patent/MA38648B1/fr unknown
- 2014-06-25 SM SM20170422T patent/SMT201700422T1/it unknown
- 2014-06-25 ES ES14740094.9T patent/ES2636652T3/es active Active
- 2014-06-25 HR HRP20171031TT patent/HRP20171031T1/hr unknown
- 2014-06-25 BR BR112015030723A patent/BR112015030723A8/pt not_active Application Discontinuation
-
2015
- 2015-11-26 PH PH12015502630A patent/PH12015502630A1/en unknown
- 2015-12-15 CL CL2015003635A patent/CL2015003635A1/es unknown
- 2015-12-22 IL IL243296A patent/IL243296B/en active IP Right Grant
-
2016
- 2016-03-11 US US15/067,915 patent/US20160194338A1/en not_active Abandoned
-
2017
- 2017-06-16 US US15/625,417 patent/US9850258B2/en active Active
- 2017-09-06 CY CY20171100943T patent/CY1119371T1/el unknown
- 2017-11-10 US US15/809,437 patent/US10106559B2/en active Active
-
2018
- 2018-09-25 US US16/140,750 patent/US10435415B2/en active Active
-
2019
- 2019-08-22 US US16/547,675 patent/US20190382416A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016523907A5 (en:Method) | ||
| JP2016523908A5 (en:Method) | ||
| JP2014521735A5 (en:Method) | ||
| JP2014508752A5 (en:Method) | ||
| CN107427516B8 (zh) | 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法 | |
| JP2016508134A5 (en:Method) | ||
| CA2925624C (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
| JP2017504611A5 (en:Method) | ||
| JP2015501783A5 (en:Method) | ||
| RU2017114346A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| CY1120248T1 (el) | Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| JP2015523397A5 (en:Method) | ||
| JP2016522835A5 (en:Method) | ||
| JP2018109022A5 (en:Method) | ||
| CY1123837T1 (el) | Ενωσεις για την χρηση στη θεραπεια μεταστασεων στον εγκεφαλο σε ασθενη με καρκινο του μαστου erbb2+ | |
| HRP20160135T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za lijeäśenje raka | |
| EA201890852A1 (ru) | Соли валбеназина и их полиморфы | |
| EP3686200A3 (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| RU2015104537A (ru) | Способы лечения стромальных опухолей желудочно-кишечного тракта | |
| JP2016528301A5 (en:Method) | ||
| JP2015508103A5 (en:Method) | ||
| JP2016530283A5 (en:Method) | ||
| WO2015042078A3 (en) | Substituted aminopyrimidine compounds and methods of use | |
| JP2014513110A5 (en:Method) | ||
| JP2014507446A5 (en:Method) |